CN117679569A

CN117679569A - Blood treatment apparatus

Info

Publication number: CN117679569A
Application number: CN202410155376.3A
Authority: CN
Inventors: 刘成一; 杨璐
Original assignee: Beijing Maibang Tiangong Medical Technology Co ltd
Current assignee: Beijing Maibang Tiangong Medical Technology Co ltd
Priority date: 2024-02-04
Filing date: 2024-02-04
Publication date: 2024-03-12
Anticipated expiration: 2044-02-04
Also published as: CN117679569B

Abstract

Embodiments of the present application provide a blood processing apparatus. The blood processing apparatus includes: a blood separator configured to be able to separate target component blood from whole blood; a blood processing machine including a first bag and a second bag; the blood processing machine is configured to perform the steps of: extracting target component blood from the blood separator and temporarily storing the target component blood in the first bag body; extracting part of target component blood from the target component blood in the first bag body to the second bag body; processing part of target component blood stored in the second bag body to obtain processed part of target component blood; storing the processed target component blood into a first bag body to update the target component blood in the first bag body, and detecting whether the updated target component blood is qualified or not; and if the blood is not qualified, continuing to extract part of the target component blood from the target component blood in the first bag body into the second bag body.

Description

Blood treatment apparatus

Technical Field

The embodiment of the application relates to the technical field of medical instruments, and more particularly relates to blood treatment equipment.

Background

In the prior art, when component blood in blood is treated by blood treatment equipment to reduce or eliminate harmful substances in the component blood, the component blood is often directly treated, and the treatment mode is low in efficiency and can easily destroy the component blood.

In view of the foregoing, there is a need to provide a new solution to the above-mentioned problems.

Disclosure of Invention

The aim of the present application is to provide a new solution for a blood treatment apparatus.

Embodiments of the present application provide a blood processing apparatus. The blood processing apparatus includes: a blood separator configured to be able to separate target component blood from whole blood;

a blood processing machine including a first bag and a second bag;

the blood processing machine is configured to perform the steps of:

extracting target component blood from the blood separator and temporarily storing the target component blood in the first bag;

extracting a part of target component blood from the target component blood of the first bag body into a second bag body;

processing part of target component blood stored in the second bag body to obtain processed part of target component blood;

storing the processed partial target component blood into the first bag body to update the target component blood in the first bag body, and detecting whether the updated target component blood is qualified or not;

and if the blood is not qualified, continuing to extract part of the target component blood from the target component blood in the first bag body into the second bag body.

Optionally, the target component blood is one of plasma, white blood cells, red blood cells or platelets.

Optionally, in the case that the target component blood is plasma, the blood processing machine further includes an illumination module, and processing a portion of the target component blood stored in the second bag specifically includes: and irradiating part of the target component blood by using an illumination module to obtain part of the processed target component blood.

Optionally, the illumination module includes an LED lamp, and the wavelength of the LED lamp is 350 nm-480 nm.

Optionally, the blood processing machine further includes a third bag body, the third bag body stores a drug therein, and the processing of a portion of the target component blood stored in the second bag body specifically further includes: and adding the medicine in the third bag body into the second bag body, mixing with part of target component blood, and treating part of target component blood added with the medicine.

Optionally, the blood processing machine further includes a light irradiation unit, and before adding the medicine in the third bag to the second bag, the blood processing machine further includes: the medicine in the third bag body is irradiated by the light irradiation unit.

Optionally, when bilirubin in plasma is processed by the illumination module and the bilirubin decomposition rate meets a specific threshold, the blood processing machine performs an operation of increasing illumination intensity, or the blood processing machine performs an operation of storing a processed portion of target component blood into the first bag body to update the target component blood in the first bag body.

Optionally, the blood separator is configured to adjust a speed of separating target constituent blood from whole blood according to a processing time of the illumination module to process the target constituent blood; and/or the illumination module is configured to adjust illumination intensity according to a speed of the blood separator separating the target component blood from the whole blood.

Optionally, the blood volume of the part of the target component blood is 5% -70% of the blood volume of the target component blood.

Optionally, the blood processing machine further performs the steps of:

and under the condition that the updated target component blood is detected to be qualified, conveying the updated target component blood to a human body.

Optionally, the blood separator is further configured to separate platelets from whole blood, the blood separator being capable of delivering the separated platelets to a human body during delivery of the updated target constituent blood to the human body by the blood processor.

Optionally, the blood separator further comprises a blood separation unit comprising a centrifuge bag, a target component blood bag and a platelet bag;

the centrifugal bag is used for storing whole blood extracted from a human body and anticoagulant conveyed from an anticoagulant unit;

the target component blood belt and the platelet bag are respectively communicated with the centrifugal bag through a pipeline, and the target component blood bag is communicated with the first bag body through a pipeline;

optionally, the blood separator further comprises a back transfusion blood storage unit, the back transfusion blood storage unit comprises a storage box and a gas bag, and the gas bag is communicated with the storage box

In the case of detecting that the updated target constituent blood is acceptable, the blood processing apparatus is capable of transferring the updated target constituent blood to a storage box.

According to the embodiment of the application, the blood treatment equipment is provided, and the blood treatment machine is used for carrying out circulation treatment on the target component blood in the first bag body so as to achieve the purpose that the target component blood is qualified. Compared with the prior art, the method can directly process the separated target component blood, and can improve the processing efficiency.

Other features of the present specification and its advantages will become apparent from the following detailed description of exemplary embodiments thereof, which proceeds with reference to the accompanying drawings.

Drawings

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the specification and together with the description, serve to explain the principles of the specification.

Fig. 1 is a flowchart illustrating steps performed by a blood processing machine according to an embodiment of the present application.

Fig. 2 is a schematic view of a blood treatment apparatus according to an embodiment of the present application.

Fig. 3 is a graph showing the relationship between bilirubin decomposition rate V and illumination intensity I.

Fig. 4 to 9 are schematic views showing the processing state of the blood processor when the blood processor processes the target component blood.

Reference numerals illustrate:

1. a blood separator; 10. a target component blood bag; 11. a platelet bag; 12. an air bag; 13. an anticoagulant bag; 14. centrifuging the bag; 15. a storage box;

2. a blood processing machine; 21. a first bag body; 22. a second bag body; 23. a third bag body; 24. an illumination module; 25. a circulation pump;

01. a first gate; 02. a second gate; 03. a third gate; 04. and a fourth gate.

Detailed Description

Various exemplary embodiments of the present application will now be described in detail with reference to the accompanying drawings. It should be noted that: the relative arrangement of the components and steps, numerical expressions and numerical values set forth in these embodiments do not limit the scope of the present application unless it is specifically stated otherwise.

The following description of at least one exemplary embodiment is merely exemplary in nature and is in no way intended to limit the application, its application, or uses.

Techniques and equipment known to those of ordinary skill in the relevant art may not be discussed in detail, but should be considered part of the specification where appropriate.

In all examples shown and discussed herein, any specific values should be construed as merely illustrative, and not a limitation. Thus, other examples of exemplary embodiments may have different values.

It should be noted that: like reference numerals and letters denote like items in the following figures, and thus once an item is defined in one figure, no further discussion thereof is necessary in subsequent figures.

In the prior art, bilirubin in blood plasma is treated by a blood treatment apparatus, and a plasma adsorption method is generally used. Bilirubin in plasma is adsorbed off, for example, by an adsorption column, but this approach has the following problems: 1) low removal efficiency, 2) high cost, 3) easy saturation of the adsorption column; in another method, bilirubin in blood plasma is treated by an illumination method, but at present, the blood plasma separated by a blood separator is directly illuminated, and excessive blood plasma is treated by illumination, so that the illumination of the blood plasma is heated unevenly, the speed of treating the blood plasma is uneven, and the treatment effect of the blood plasma is affected.

Embodiments of the present application provide a blood processing apparatus. Referring to fig. 1 and 2, and fig. 4-9, a blood processing apparatus includes: a blood separator 1 and a blood processor 2. The blood separator 1 is configured to be able to separate target component blood from whole blood.

The blood processing machine 2 comprises a first bag 21 and a second bag 22. The blood treatment machine 2 is configured to be able to perform the following steps:

s101: extracting target blood components from the blood separator 1 and temporarily storing the target blood components in the first bag 21;

s102: extracting a part of the target component blood from the target component blood of the first bag 21 into the second bag 22;

s103: processing a portion of the target component blood stored in the second bag 22 to obtain a processed portion of the target component blood;

s104: storing the processed target component blood into the first bag body 21 to update the target component blood in the first bag body 21, and detecting whether the updated target component blood is qualified or not;

s105: in the case of failure, the step of extracting a part of the target component blood from the target component blood in the first bag 21 into the second bag 22 is continued.

In an embodiment of the present application, a blood processing apparatus is provided, which mainly includes a blood separator 1 and a blood processing machine 2.

The blood separator 1 may separate target component blood from whole blood by centrifugation or the like. Wherein whole blood can be obtained from a human body. Wherein the target component blood can be blood plasma, white blood cells, red blood cells or blood platelets, etc. For example, a high content of bilirubin in blood plasma affects human health, and the blood plasma is treated by the blood treatment machine 2, and the target component blood may be blood plasma. For example, when the number of white blood cells or other index does not meet the human requirement, the white blood cells need to be treated by the blood treatment machine 2, and the target component blood may be white blood cells. For example, when the number of red blood cells or other index does not meet the human requirement, the red blood cells need to be processed by the blood processing machine 2, and the target component blood may be red blood cells.

The blood treatment apparatus can thus achieve targeted treatment of blood of different target components, which are selected by the blood separator 1 (e.g. plasma, white blood cells, red blood cells or platelets, etc.), so as to treat the plasma, white blood cells, red blood cells or platelets targeted.

The blood processing machine 2 includes a first bag 21, wherein the first bag 21 is used for temporarily storing the target component blood. For example, the blood processor 2 extracts the target component blood from the blood separator 1 and temporarily stores the target component blood in the first bag 21. Wherein the blood separator 1 may stop separating the whole blood or the blood separator 1 may not stop separating the whole blood (e.g., the separation speed of the blood separator 1 from the whole blood may be adjusted so that the blood separator does not stop separating the whole blood) during the process of extracting the target component blood from the blood separator 1 by the blood processor 2, wherein whether the blood separator 1 stops separating the whole blood may be determined according to the separation speed of the blood separator 1 and the processing speed and processing time of the target component blood by the blood processor 2. Preferably, in the process of extracting the target component blood from the blood separator 1 by the blood processor 2, the blood separator 1 may not stop separating the whole blood by adjusting the separation speed of the whole blood from the blood separator 1, so that the whole process from the blood extraction to the whole blood separation and the target component blood processing is an uninterrupted process, which can be also understood as: the whole process from blood drawing to whole blood separation and blood treatment of the target component is a coherent process.

The blood processing machine 2 includes a second bag 22, and the first bag 21 and the second bag 22 can communicate through a pipeline. The second bag 22 is for temporarily storing a portion of the target component blood obtained from the first bag 21, and the portion of the target component blood is a portion of the blood volume of the target component blood in the first bag 21.

In the embodiment of the present application, the blood processing apparatus includes the blood processing machine 2 configured to perform the processing of the target component blood by performing steps S101 to S105.

In step S101, the blood processor 2 needs to extract the target component blood from the blood separator 1 and temporarily store the target component blood in the first bag 21. For example, the blood processor 2 may extract a preset amount of target component blood from the blood separator 1, and perform a small number of multiple circulation processes on the preset amount of target component blood, so as to achieve the purpose of improving the effect of processing the target component blood, for example, the target component blood is blood plasma, and through the small number of multiple circulation processes, the conversion rate of bilirubin in the blood plasma can be improved. Wherein the predetermined amount of the target component blood may be less than 300ml or less than 100ml to substantially balance the human heart fluid.

In step S102, the blood processing machine 2 needs to extract a part of the target component blood from the target component blood in the first bag 21 into the second bag 22. For example, the first bag 21 and the second bag 22 are connected together by a pipe line through which a part of the target component blood from the target component blood of the first bag 21 can be extracted to the second bag 22.

The amount of the target component blood (volume or capacity) may be a part of the amount of the target component blood (volume or capacity), for example, the amount of the target component blood may be one fifth or one tenth or one half of the amount of the target component blood, and the present embodiment may not particularly limit the amount of the target component blood, and may select and process a proper amount of the target component blood in combination with the processing method of the target component blood when the capacity of the second bag 22 allows. For example, when the target component blood is plasma, a part of the target component blood is processed by the illumination method, and when the capacity of the second bag 22 allows, an appropriate amount of the part of the target component blood can be selected by combining parameters such as the illumination intensity.

In step S103, the blood processor 2 processes a portion of the target component blood stored in the second bag 22 to obtain a processed portion of the target component blood. In this embodiment, the treatment of a portion of the target blood in the second bag 22 is performed by selecting a different treatment method according to the type of the target blood. For example, when the target component blood is plasma, bilirubin in the plasma is treated by a light irradiation method. Wherein different irradiation powers can be selected to irradiate the target component blood corresponding to different target component blood.

In this step, the blood processor 2 processes a portion of the target component blood stored in the second bag 22, and in this embodiment, the portion of the target component blood is processed directly in the first bag 21, so that the rate of processing a portion of the target component blood each time can be increased, and the processing rate of the target component blood in the first bag 21 can be improved. For example, by taking the target component blood as blood plasma and treating bilirubin in the blood plasma in an illumination manner, only a part of the blood plasma in the second bag body 22 is subjected to illumination treatment each time, so that the illumination of the part of the blood plasma is uniform, the conversion rate of the part of the blood plasma is uniform, and the conversion rate of the bilirubin in the part of the blood plasma is improved.

In step S104, after the processed target component blood is obtained in the previous step (step S103), the processed target component blood needs to be stored in the first bag 21 to update the target component blood in the first bag 21, and thus the updated first bag 21 includes the processed target component blood and the unprocessed target component blood. The processing effect of the processed target component blood and the unprocessed target component blood contained in the updated first bag 21 is improved to some extent as compared with the whole unprocessed target component blood contained in the non-updated first bag 21. For example, in the case where the target component blood is plasma and bilirubin in the plasma is treated, the whole of the inside of the first bag 21 is untreated, and thus the concentration of bilirubin in the plasma in the first bag 21 is high. The first bag 21 after the refresh includes the treated plasma and the untreated plasma, and the treated plasma and the untreated plasma are mixed, so that the concentration of bilirubin in the plasma in the first bag 21 after the refresh is reduced. The concentration of bilirubin in the plasma in the first bag 21 that is updated once may be detected, and if the detection is failed, step S105 is required to be executed, that is, if the detection is failed, the step of extracting a part of the target component blood from the target component blood in the first bag 21 into the second bag 22 is continued.

In step S105, when it is detected that the target component blood in the first bag 21 that has been updated once is not acceptable, it is necessary to perform steps S102 to S105 in a loop. When it is detected that the target component blood in the first bag 21 that has been updated once is acceptable, it is not necessary to perform steps S102 to S105 in a loop.

For example, when it is detected that the target component blood in the first bag 21 is not acceptable once updated, the steps S102 to S105 are cyclically executed:

wherein when step S102 is cyclically executed (for example, step S102 is executed a second time, or step S102 is executed an nth time), a part of the target component blood is extracted from the updated target component blood in the first bag 21 into the second bag 22, and the blood volume of the part of the component blood extracted in this step may be the same as or different from the blood volume of the part of the target component blood extracted last time.

When step S103 is executed in a loop (for example, step S103 is executed a second time or step S103 is executed an nth time), a part of the target blood component stored in the second bag 22 is processed, and in this step, the processing manner of the part of the target blood component stored in the second bag 22 is the same as or different from the processing manner of the part of the target blood component stored in the second bag 22 last time. When the treatment mode of the target blood stored in the second bag 22 in this step is the same as the treatment mode of the target blood stored in the second bag 22 last time, the treatment parameters of the treatment mode can be appropriately adjusted. For example, the target component blood is plasma, and bilirubin in the plasma is reduced by an illumination method, and the intensity, illumination time, and the like of each illumination can be appropriately adjusted.

In the case of performing step S104 in a loop (for example, performing step S104 a second time, or performing step S104 an nth time), a portion of the target component blood after the treatment is stored in the first bag 21 to update the updated target component blood in the first bag 21 again, for example, the target component blood is taken as blood plasma, bilirubin in the blood plasma is treated as example, and the whole of the non-updated first bag 21 is non-treated blood plasma, so that the concentration of bilirubin in the blood plasma in the non-updated first bag 21 is high. The first bag 21 after the refresh includes the treated plasma and the untreated plasma, and the treated plasma and the untreated plasma are mixed, so that the concentration of bilirubin in the plasma in the first bag 21 after the refresh is reduced. The updated target component blood in the first bag 21 is updated again, and thus the concentration of bilirubin in the plasma in the first bag 21 after a plurality of times of updating is gradually decreased. In this step, the updated target component blood in the first bag 21 is updated again, and the updated target component blood is detected, and when the updated target component blood is detected to be acceptable, it is not necessary to execute step S105; when the target component blood detection updated again is not acceptable, step S105 is also required to be performed until the target component blood detection in the first bag 21 is acceptable.

Therefore, in the embodiment of the present application, a blood treatment apparatus is provided, in which the blood treatment machine 2 is used to perform the circulation treatment on the target component blood in the first bag 21, so as to achieve the purpose of qualifying the target component blood. Compared with the prior art, the method can directly process the separated target component blood, and can improve the processing efficiency.

In one embodiment, the target constituent blood is one of plasma, white blood cells, red blood cells, or platelets.

Specifically, the target component blood is plasma, and bilirubin in the plasma can be treated. By adopting the blood treatment equipment provided by the embodiment of the application, when bilirubin in blood plasma is treated, the blood plasma in the first bag body 21 is updated once in each cycle, and the concentration of the bilirubin in the blood plasma in the first bag body 21 is reduced.

When the target blood component is white blood cells, for example, when the number of white blood cells is large, white blood cells can be treated. By adopting the blood treatment equipment provided by the embodiment of the application, when white blood cells are treated, the white blood cells in the first bag body 21 are updated once in each cycle, and the number of the white blood cells in the first bag body 21 is reduced.

When the target component blood is red blood cells, for example, when the number of red blood cells is small, the red blood cells can be treated. By adopting the blood treatment equipment provided by the embodiment of the application, when the erythrocytes are treated, the erythrocytes in the first bag body 21 are updated once in each cycle, and the number of the erythrocytes in the first bag body 21 is increased.

The target component blood is platelets, and for example, platelets can be treated when the number of platelets is small.

In one embodiment, in the case that the target blood component is plasma, the blood processing machine 2 further includes an illumination module 24, and processing a portion of the target blood component stored in the second bag 22 specifically includes: a portion of the target constituent blood after the target constituent blood acquisition process is irradiated by the irradiation module 24.

In this embodiment, when the target blood component is blood plasma, the illumination module 24 is disposed in the blood processing apparatus, and a portion of the blood plasma in the second bag 22 is processed by the illumination module 24, so as to achieve the purpose of reducing bilirubin in the blood plasma. For example, the illumination module 24 is specifically a module for bilirubin treatment.

Alternatively, in the case where the target constituent blood is white blood cells, a white blood cell processing module is provided in the blood processing apparatus, for example, the white blood cell processing module may be the illumination module 24 or other processing modules.

Alternatively, in case the target constituent blood is red blood cells, a red blood cell processing module is provided in the blood processing apparatus, for example the red blood cell processing module may be the illumination module 24 or other processing module.

In one embodiment, the illumination module 24 includes an LED lamp having a wavelength of 350nm to 480nm. For example, the LED lamp may be a blue light emitting LED lamp.

Specifically, bilirubin is decomposed into isomers of bilirubin under blue light irradiation, and the isomers of bilirubin are dissolved in water, so that the isomers of bilirubin can be easily and quickly discharged out of the body through urine and feces, thereby achieving the aim of reducing bilirubin in the body.

Therefore, the direct irradiation of plasma can be realized by installing an LED blue light in the blood treatment machine 2, wherein the wavelength of the LED blue light is preferably in the range of 420nm to 470nm, and other wavelengths are auxiliary, so that the sterilization and disinfection can be assisted.

Optionally, the operation panel of the blood processor 2 can be used for controlling the working mode, the illumination wavelength, the illumination time and intensity, and controlling the on-off of the illumination, so as to achieve the purposes of flexibly regulating and controlling and reasonably and effectively reducing the bilirubin content according to actual conditions.

In one embodiment, the blood processing machine 2 further includes a third bag 23, where the third bag 23 stores a drug, and processing a portion of the target component blood stored in the second bag 22 specifically further includes: the medicine in the third bag 23 is added to the second bag 22 and mixed with a part of the target component blood, and a part of the target component blood to which the medicine is added is treated.

Specifically, the blood processing machine 2 further includes a third bag 23, and the third bag 23 stores a medicine. Wherein the medicine in the third bag 23 has the following functions: sterilization or other beneficial effects are achieved by adding drugs when treating plasma, white blood cells or red blood cells. For example, in order to inactivate viruses, for patients who are infected with viruses and bacteria, such as hepatitis patients, a photosensitizer may be added to the third bag 23, and then the photosensitizer in the third bag 23 is added to the second bag 22, so that the photosensitizer is mixed with a portion of the target component blood, and the target component blood mixed with the photosensitizer in the second bag 22 is processed by the illumination module 24 or other processing module. Wherein the photosensitizer is preferably riboflavin.

In one embodiment, the blood processing machine 2 further includes a light irradiation unit, and before adding the medicine in the third bag 23 to the second bag 22, the method may further include: the medicine in the third bag 23 is irradiated by the light irradiation unit.

In this embodiment, the blood processing machine 2 further includes a light irradiation unit that processes the medicine in the third bag 23. For example, before the medicine in the third bag 23 is added to the second bag 22, the medicine (photosensitizer) in the third bag 23 may be treated by the light irradiation unit, and the treated medicine may be mixed with a part of the target component blood in the second bag 22, and after the medicine is sufficiently mixed, the treatment of the part of the target component blood mixed with the medicine in the second bag 22 may be continued, or the part of the target component blood mixed with the medicine may be directly returned.

Alternatively, the wavelength of the light irradiation unit may be selectively increased UVA, UVB, UVC to increase the therapeutic effect.

In one embodiment, when bilirubin in plasma is processed by the illumination module 24 and the bilirubin decomposition rate satisfies a specific threshold, the blood processing machine 2 performs an operation of increasing illumination intensity, or the blood processing machine 2 performs an operation of storing a processed portion of target component blood into the first bag 21 to update the target component blood in the first bag 21.

Specifically, there is a correlation between the bilirubin decomposition rate V, the bilirubin concentration B, and the change in the illumination intensity I. When bilirubin is decomposed at the partial derivative of velocity VIs 0 or when the partial derivative of the bilirubin decomposition rate V is less than or equal to a certain threshold TH (the certain threshold TH is preferably the partial derivative of the bilirubin decomposition rate V +.>One third of the maximum value), the bilirubin decomposition rate can be considered too low, and the illumination intensity I can be increased or the illumination intensity can be adjusted to the maximum illumination intensity; if the bilirubin decomposition rate is not low due to the light intensity factor, the bilirubin decomposition in the second bag 22 is considered to be completed, and at this time, a part of the processed target component blood may be stored in the first bag 21 to update the target component blood in the first bag 21.

Alternatively, fig. 3 shows a graph of bilirubin decomposition rate V versus illumination intensity I. The bilirubin decomposition rate and the light intensity change nonlinearly, and a change threshold exists because the bilirubin decomposition rate and the light intensity change nonlinearly. When the light intensity I is smaller than the I1 (threshold), the decomposition rate of bilirubin is low, and after exceeding the I1 (threshold), the bilirubin decomposition rate is rapidly increased, so that the light intensity I is more than the I1 (threshold) for improving the bilirubin decomposition efficiency.

Optionally, excessive heat may be generated when the illumination intensity is too high, and in order to avoid that the total energy of illumination exceeds the standard, in the embodiment of the present application, the target component blood is processed through a small amount of multiple cycles, so that a portion of the target component blood in the second bag 22 may be processed without excessively high illumination intensity and excessively long illumination time. In addition, by treating a portion of the target constituent blood in the second bag 22, a portion of the target constituent blood is heated more uniformly and the rate of treating the target constituent blood is more uniform.

Optionally, the temperature T of the illumination module 24 should be less than 39 degrees, preferably less than 36 degrees, wherein the temperature of the illumination module 24 is determined by the temperature in the first bag 21, the speed V of the circulation pump 25 (the second bag 22 and the first bag 21 are provided with the circulation pump 25 before), the irradiation heat P1 of the illumination module 24, and the heat dissipation power P2 of the illumination module 24.

Alternatively, the target constituent blood in the first bag 21 is updated once every cycle, preferably 3 times.

In one embodiment, the blood separator 1 is configured to adjust the speed of separating target constituent blood from whole blood according to the processing time of the processing target constituent blood of the illumination module 24; and/or the illumination module 24 is configured to adjust the illumination intensity according to the speed at which the blood separator 1 separates the target component blood from the whole blood.

Specifically, the blood separator 1 is configured to adjust the speed of separating the target component blood from the whole blood according to the processing time of processing the target component blood by the illumination module 24, and the illumination module 24 is configured to adjust the illumination intensity according to the speed of separating the target component blood from the whole blood by the blood separator 1, so that the interactive communication and the co-cooperation of the blood separator 1 and the blood processor 2 can be realized, which co-cooperation exceeds the simple combination superposition of the blood separator 1 and the blood processor 2. In the case of the extracorporeal total blood volume being fixed, the blood separator 1 can adjust the speed of separating plasma/white blood cells/red blood cells/platelets according to the working efficiency of the illumination module 24, and the illumination module 24 can also adjust the blood volume and the light intensity of single irradiation according to the separation speed of the blood separator 1. The mechanism by which the blood separator 1 and blood processor 2 work together significantly improves efficiency over the serial flow of retreatment after separation is completed.

Thus, in this embodiment, the blood processing apparatus can achieve intelligent control of the system in terms of bilirubin breakdown rate and its partial derivative, illumination intensity of the illumination module 24, illumination time of the illumination module 24 (i.e., processing time for processing the target constituent blood), blood sampling rate, and feedback rate, so that the blood processing apparatus has consistency.

In one embodiment, the blood volume of the portion of the target constituent blood is 5% -70% of the blood volume of the target constituent blood.

In this embodiment, the blood volume of a part of the target component blood is defined, for example, the blood volume of a part of the target component blood is 10%, 20% or 30% or 50% of the blood volume of the target component blood. The blood volume of a part of the target component blood can be determined according to parameters such as the processing time of the illumination module 24, so long as the illumination uniformity of the part of the target component blood can be realized, and the processing efficiency is improved.

In one embodiment, the blood treatment machine 2 further performs the steps of:

In this embodiment, in the case where the updated target component blood is detected to be acceptable, the target component blood may be returned to the human body. Therefore, in the aspect of reducing bilirubin content by taking the target component blood as blood plasma, compared with the traditional blood changing treatment, the method does not need to carry out allogeneic blood matching, avoids adverse reaction and reduces treatment flow.

In a specific embodiment, the blood processing machine 2 includes a first bag 21 and a second bag 22, where the first bag 21 and the second bag 22 are connected by a first pipeline and a second pipeline, and a portion of the target component blood in the first bag 21 can be obtained into the second bag 22 through the first pipeline, and a portion of the target component blood in the processed second bag 22 can be transferred into the first bag 21 through the second pipeline. For example, a portion of the blood of the target component in the first bag 21 is transferred from the first line to the second bag 22. For example, a portion of the target component blood processed in the second bag 22 is transferred into the first bag 21 through the second line.

The blood processing machine 2 further comprises a third bag 23, the third bag 23 and the second bag 22 being connected by a pipeline.

Optionally, a bubble sensor may be disposed on the first conduit, and detection of the blood flow of a portion of the target component in the first conduit may be achieved by the bubble sensor.

Optionally, a pressure sensor and a bubble sensor may be provided on the second line to enable detection of the target constituent blood in the second line.

Alternatively, a circulation pump 25 may be provided on the second line, and the target component blood processed in the second bag 22 may be transferred into the first bag 21 through the circulation pump 25.

Alternatively, when the target blood component is plasma and bilirubin in the plasma is required to be treated, a bilirubin sensor may be provided in the first bag 21, and the bilirubin level of the updated target blood component in the first bag 21 may be detected by the bilirubin sensor (bilirubin detector).

Wherein the blood treatment machine 2 comprises a first gate body 01, a second gate body 02, a third gate body 03 and a fourth gate body 04, and the switch of the gate bodies is matched with the circulating pump 25, so that the blood treatment machine 2 can be switched among a plurality of states. The blood processing machine 2 includes a plurality of states including: the state in which the target component blood is transferred to the first bag 21, the state in which the medicine is added to the second bag 22, the state in which the medicine is restored, the state in which the medicine is mixed with part of the target component blood, the state in which the treatment is performed on part of the target component blood in the second bag 22, and the state in which the target component blood is returned.

Referring to fig. 4, the target component blood separated in the blood separator 1 is transferred to the first bag 21, and the arrow in fig. 4 shows the flow direction of the target component blood separated in the blood separator 1.

Referring to fig. 5, a state in which the medicine in the third bag 23 is added to the second bag 22 is shown, and arrows in fig. 5 show the flow direction of the medicine in the third bag 23.

The state of adding the drug into the second bag 22 shown in fig. 5 is an optional state, and when the drug is not required to be added to treat the target blood, the drug in the third bag 23 may not be required to be added into the second bag 22.

Referring to fig. 6, a state in which the medicine in the second bag 22 is returned to the third bag 23 is shown, and the arrow in fig. 6 shows the flow direction of the medicine in the second bag 22.

It should be noted that the drug restocking state shown in fig. 6 is an optional state. When the drug treatment is required, referring to fig. 5, the drug may be extracted first to reach the second bag 22, and the drug may be directly mixed with a part of the target component blood, and the part of the target component blood mixed with the drug may be treated.

If the required medicine amount is large, the medicine can be firstly circularly treated by the illumination treatment unit or the illumination module 24, and then the medicine is restored after the medicine is circularly treated, and the medicine is restored to the third bag body 23 for storage. When the medicine is mixed with a part of the target blood, a proper amount of the processed medicine is obtained from the third bag 23, and the medicine is mixed with a part of the target blood in the second bag 22.

Referring to fig. 7, the medicine in the third bag 23 is stored in the second bag 22, and the target blood component in the first bag 21 is partially stored in the second bag 22, and the medicine and the target blood component are partially mixed.

Referring to fig. 8, a state in which a part of the target component blood in the second bag 22 is circulated by the illumination module 24 is shown.

Referring to fig. 9, the target component blood after the treatment in the first bag 21 is returned to the human body. In this embodiment, instead of directly transferring the target component blood in the first bag 21 to the human body, the processed target component blood in the first bag 21 is transferred to the second bag 22, and then the processed target component blood is transferred to the human body by the circulation pump 25, so that part of the target component blood in the pipeline and part of the target component blood in the second bag 22 can be transferred to the human body.

Optionally, the blood processing machine 2 further comprises a plurality of temperature sensors, which may be used to detect the temperature in the first bag 21, the temperature in the second bag 22, the target constituent blood return temperature, etc.

In one embodiment, the blood separator 1 is further configured to separate platelets from whole blood, the blood separator 1 being capable of delivering the separated platelets to a human body during delivery of the updated target component blood to the human body by the blood processor 2.

In this embodiment, blood separation separates platelets from whole blood, so that platelets can be filtered out when the target component blood is processed, and platelets can be re-infused back into the body during the return infusion of the target component blood into the body. Because the exposure to light may activate platelets if they are contained in plasma or whole blood, a risk of clotting may occur.

In one embodiment, the blood separator 1 comprises a blood separation unit comprising a centrifuge bag 14, a target component blood bag 10 and a platelet bag 11;

the centrifugal bag 14 is used for storing whole blood and anticoagulant extracted from a human body;

the target component blood bag 10 and the platelet bag 11 are respectively communicated with the centrifugal bag through a pipeline, and the target component blood bag 10 is communicated with the first bag body 21 through a pipeline.

In particular, the blood separator 1 comprises a centrifuge bag, which may for example be an annular centrifuge bag (an annular centrifuge bag being a kind of plastic channel located in specially designed grooves in the centrifuge bowl) which is then rotated at high speed in the centrifuge. As whole blood rotates in the annular centrifuge bag, the target components blood and platelets can be separated.

Wherein the target component blood bag 10 is required to be communicated with the first bag body 21, so that the target component blood separated by the blood separator 1 can be conveyed to the first bag body 21.

In an alternative embodiment, the blood separator 1 comprises an anticoagulant bag 13, the anticoagulant bag 13 for storing an anticoagulant.

When whole blood is drawn from a human body to a blood separation unit, anticoagulant may be delivered to a centrifuge bag of the blood separation unit. For example, anticoagulant may be delivered into the body during return of the target constituent blood to the body. Alternatively, the centrifuge bag 14 in the blood separator 1 is a sterile, pyrogen-free device that rotates at high speed in the centrifuge to separate whole blood into blood components: platelets, plasma, erythrocytes and leukocytes.

In one embodiment, the blood separator 1 further comprises a back transfusion blood storage unit comprising a storage box 15 and a gas bag 12, the gas bag 12 being in communication with the storage box 15;

in the case where the updated target component blood is detected to be acceptable, the blood processing machine 2 can transfer the updated target component blood to the storage box 15.

In this embodiment, in the case where the updated target component blood is detected to be acceptable, the blood processor 2 transfers the updated target component blood to the storage box 15. The purpose of the air bag 12 is to store air trapped in the device prior to blood return and to recharge the device after the completion of the back transfusion to equalize the pressure.

Alternatively, the blood processing apparatus provided in the embodiments of the present application is applicable to a single needle mode or a double needle mode. For example, the blood treatment device is suitable for a single needle mode, namely, one arm of a human body simultaneously realizes a blood drawing process and a blood returning process. For example, the blood processing apparatus is adapted for use in a two-needle manner, i.e. one arm performs a blood drawing process and the other arm performs a blood return process.

The foregoing embodiments mainly describe differences between the embodiments, and as long as there is no contradiction between different optimization features of the embodiments, the embodiments may be combined to form a better embodiment, and in consideration of brevity of line text, no further description is given here.

Although some specific embodiments of the present application have been described in detail by way of example, it should be understood by those skilled in the art that the above examples are for illustration only and are not intended to limit the scope of the present application. It will be appreciated by those skilled in the art that modifications may be made to the above embodiments without departing from the scope and spirit of the present application. The scope of the application is defined by the appended claims.

Claims

1. A blood processing apparatus, comprising:

a blood separator (1), the blood separator (1) being configured to be able to separate target component blood from whole blood;

a blood processing machine (2), the blood processing machine (2) comprising a first bag (21) and a second bag (22);

the blood treatment machine (2) is configured to be able to perform the following steps:

extracting target component blood from the blood separator (1) and temporarily storing the target component blood in the first bag (21);

extracting a part of target component blood from the target component blood of the first bag (21) into a second bag (22);

processing a portion of the target component blood stored in the second bag (22) to obtain a processed portion of the target component blood;

storing the processed target component blood into the first bag body (21) to update the target component blood in the first bag body (21), and detecting whether the updated target component blood is qualified or not;

if the blood is not acceptable, the step of extracting a part of the target component blood from the target component blood in the first bag (21) into the second bag (22) is continued.

2. The blood processing apparatus of claim 1, wherein the target constituent blood is one of plasma, white blood cells, red blood cells, or platelets.

3. The blood treatment apparatus according to claim 1, wherein, in case the target constituent blood is plasma, the blood treatment machine (2) further comprises an illumination module (24);

wherein the processing of a portion of the target constituent blood stored in the second bag (22) specifically includes: a part of the target component blood after the acquisition processing is irradiated by an irradiation module (24).

4. A blood treatment apparatus according to claim 3, wherein the illumination module (24) comprises LED lamps with a wavelength of 350 nm-480 nm.

5. The blood treatment apparatus according to any one of claims 1 to 4, wherein the blood treatment machine (2) further comprises a third bag (23), wherein the third bag (23) stores a drug, and wherein the treatment of a portion of the target blood component stored in the second bag (22) specifically further comprises: and adding the medicine in the third bag body (23) into the second bag body (22) to be mixed with part of the target component blood, and processing the part of the target component blood added with the medicine.

6. The blood treatment apparatus according to claim 5, wherein the blood treatment machine (2) further comprises a light irradiation unit, further comprising, before adding the drug in the third bag (23) to the second bag (22): the medicine in the third bag (23) is irradiated by the light irradiation unit.

7. A blood processing apparatus according to claim 3, wherein the blood processing machine (2) performs an operation of increasing the illumination intensity in the case where bilirubin in the plasma is processed by the illumination module (24) and the bilirubin decomposition rate satisfies a certain threshold, or the blood processing machine (2) performs an operation of storing a processed portion of the target component blood into the first bag (21) to update the target component blood in the first bag (21).

8. A blood processing apparatus according to claim 3, wherein the blood separator (1) is configured to adjust the speed at which the target constituent blood is separated from the whole blood in accordance with the processing time at which the illumination module (24) processes the target constituent blood; and/or the illumination module (24) is configured to adjust the illumination intensity according to the speed of the blood separator (1) separating the target component blood from the whole blood.

9. The blood processing apparatus according to claim 1, wherein the blood volume of the partial target component blood is 5% -70% of the blood volume of the target component blood.

10. The blood treatment apparatus according to claim 1, wherein the blood treatment machine (2) further performs the steps of:

11. The blood processing apparatus of claim 10, wherein the blood separator (1) is further configured to separate platelets from whole blood, the blood separator (1) being capable of delivering the separated platelets to a human body during delivery of the updated target component blood to the human body by the blood processor (2).

12. The blood processing apparatus according to claim 1, wherein the blood separator (1) comprises a blood separation unit comprising a centrifuge bag (14), a target component blood bag (10) and a platelet bag (11);

the centrifuge bag (14) is used for storing whole blood and anticoagulant extracted from a human body;

the target component blood bag (10) and the platelet bag (11) are respectively communicated with the centrifugal bag (14) through pipelines, and the target component blood bag (10) is communicated with the first bag body (21) through pipelines.

13. The blood processing apparatus of claim 12, wherein the blood separator (1) further comprises a back transfusion blood storage unit comprising a storage box (15) and an air bag (12), the air bag (12) being in communication with the storage box (15);

the blood processing machine (2) is capable of transferring the updated target component blood to the storage box (15) when the updated target component blood is detected to be acceptable.